PHARMANUTRA S.P.A. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 53 EUR | -1.49% |
|
-3.99% | -6.03% |
| Apr. 15 | PharmaNutra Gets Approvals to Merge Subsidiaries | MT |
| Apr. 15 | PharmaNutra approves merger of Junia Pharma and Alesco | AN |
| Sales 2024 * | 115M 123M | Sales 2025 * | 131M 140M | Capitalization | 517M 553M |
|---|---|---|---|---|---|
| Net income 2024 * | 18M 19.23M | Net income 2025 * | 21M 22.43M | EV / Sales 2024 * | 4.44 x |
| Net cash position 2024 * | 6.37M 6.8M | Net cash position 2025 * | 16.57M 17.7M | EV / Sales 2025 * | 3.81 x |
| P/E ratio 2024 * |
28.7
x | P/E ratio 2025 * |
24.2
x | Employees | 105 |
| Yield 2024 * |
1.65% | Yield 2025 * |
1.93% | Free-Float | 34.33% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 week | -0.19% | ||
| Current month | -5.61% | ||
| 1 month | -9.12% | ||
| 3 months | -7.24% | ||
| 6 months | +4.87% | ||
| Current year | -4.61% |
1 week
52.70
56.20
1 month
52.7060.10
Current year
52.7063.50
1 year
43.5563.50
3 years
35.3080.00
5 years
16.6580.00
10 years
12.0080.00
| Managers | Title | Age | Since |
|---|---|---|---|
Andrea Lacorte
CEO | Chief Executive Officer | - | 02-12-31 |
| Chief Tech/Sci/R&D Officer | - | - | |
Carlo Volpi
COO | Chief Operating Officer | - | 08-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Giovanna Zanotti
BRD | Director/Board Member | 52 | 20-08-31 |
Andrea Lacorte
CEO | Chief Executive Officer | - | 02-12-31 |
Carlo Volpi
COO | Chief Operating Officer | - | 08-12-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 10 M€ | -3.35% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-18 | 53 | -1.49% | 3 597 |
| 24-04-17 | 53.8 | 0.00% | 2,501 |
| 24-04-16 | 53.8 | +0.75% | 5,423 |
| 24-04-15 | 53.4 | -2.91% | 14,098 |
| 24-04-12 | 55 | -0.36% | 1,963 |
Real-time Borsa Italiana, April 17, 2024 at 11:44 am EDT
More quotes
Pharmanutra SpA is an Italy-based company engaged in the healthcare industry. The Company develops nutraceutical products and medical devices. It focuses on studying and producing formulations that are backed up in scientific research. It is able to cover all stages of the development of a product, from its design, formulation and registration to its marketing, distribution and training of its commercial representatives. The Company offers Gestalys DHA, a nutritional supplement; Cetilar, a massage coadiuvant, improves and brings relief to joints affected by osteoarthritis; Cetilar patch, a transdermic patch containing a concentrated formulation of cetylated fatty acids (CFA) esters; SiderAL Forte; CardioSiderAL; SiderAL Folico; SiderAL; Bonecal and Novomega, among others.
Sector
Pharmaceuticals
Calendar
2024-05-12
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
53.8
EUR
Average target price
80.67
EUR
Spread / Average Target
+49.94%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -4.61% | 550M | |
| +28.79% | 676B | |
| +24.81% | 554B | |
| -7.64% | 349B | |
| +15.00% | 318B | |
| +5.99% | 291B | |
| +2.47% | 210B | |
| -0.02% | 204B | |
| -9.98% | 194B | |
| -11.71% | 144B |
- Stock Market
- Equities
- PHN Stock
